
ADMA Biologics Faces Class Action Lawsuit Over Revenue Allegations
Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to seek appointment as lead plaintiff in a federal class action lawsuit, following allegations that the biopharmaceutical firm misled shareholders regarding its internal revenue growth and financial controls.





















